220 related articles for article (PubMed ID: 21573085)
1. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.
Hayes KC
Neuropsychiatr Dis Treat; 2011; 7():229-39. PubMed ID: 21573085
[TBL] [Abstract][Full Text] [Related]
2. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
3. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
5. Treatment of walking impairment in multiple sclerosis with dalfampridine.
Blight AR
Ther Adv Neurol Disord; 2011 Mar; 4(2):99-109. PubMed ID: 21694807
[TBL] [Abstract][Full Text] [Related]
6. Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets.
Henney HR; Blight AR
Degener Neurol Neuromuscul Dis; 2012; 2():53-64. PubMed ID: 30890878
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
8. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
9. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.
Weir S; Torkin R; Henney HR
Curr Med Res Opin; 2013 Dec; 29(12):1627-36. PubMed ID: 23157467
[TBL] [Abstract][Full Text] [Related]
12. Dalfampridine: a new agent for symptomatic management of multiple sclerosis.
McDonald S; Clements JN
Am J Health Syst Pharm; 2011 Dec; 68(24):2335-40. PubMed ID: 22135060
[TBL] [Abstract][Full Text] [Related]
13. Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.
Sahraian MA; Maghzi AH; Etemadifar M; Minagar A
J Cent Nerv Syst Dis; 2011; 3():87-93. PubMed ID: 23861641
[TBL] [Abstract][Full Text] [Related]
14. Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.
Crayton H; Sidovar M; Wulf S; Guo A
Patient; 2015 Jun; 8(3):283-91. PubMed ID: 25475652
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
Lugaresi A
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
[TBL] [Abstract][Full Text] [Related]
16. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Foschi M; Lugaresi A
Expert Opin Pharmacother; 2019 Aug; 20(11):1309-1320. PubMed ID: 31237780
[No Abstract] [Full Text] [Related]
17. Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.
Hersh C; Rae-Grant A
Ther Adv Neurol Disord; 2012 Jul; 5(4):199-204. PubMed ID: 22783369
[TBL] [Abstract][Full Text] [Related]
18. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
19. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
Egeberg MD; Oh CY; Bainbridge JL
Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
[TBL] [Abstract][Full Text] [Related]
20. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Pikoulas TE; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]